Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Estradiol acetate (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Acronyms PHOEBE
Most Recent Events
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.
- 10 Jul 2024 Planned initiation date changed from 1 May 2024 to 1 Aug 2024.
- 12 Mar 2024 Planned initiation date changed from 1 Feb 2024 to 1 May 2024.